BioAge Labs doses first patient in Phase 2 QUELL-DME trial of oral NLRP3 inhibitor BGE-102
BIOA•BioAge Labs dosed the first participant in its Phase 2 QUELL-DME trial of oral BGE-102 for diabetic macular edema, with topline data expected in the second half of 2027.
1. Trial begins
The trial is testing BGE-102 alone or with standard anti-VEGF injections, aiming to show vision benefits over 12 weeks of dosing. The readout is expected to shape development plans for other retinal diseases tied to NLRP3-driven inflammation, including geographic atrophy.
